- Home
- SHEN vs DNTH Comparison
SHEN vs DNTH Comparison
Compare SHEN & DNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SHEN
- DNTH
- Stock Information
- Founded
- SHEN 1902
- DNTH 2015
- Country
- SHEN United States
- DNTH United States
- Employees
- SHEN N/A
- DNTH N/A
- Industry
- SHEN Telecommunications Equipment
- DNTH Biotechnology: Pharmaceutical Preparations
- Sector
- SHEN Telecommunications
- DNTH Health Care
- Exchange
- SHEN Nasdaq
- DNTH Nasdaq
- Market Cap
- SHEN 673.1M
- DNTH 651.8M
- IPO Year
- SHEN N/A
- DNTH N/A
- Fundamental
- Price
- SHEN $13.21
- DNTH $23.39
- Analyst Decision
- SHEN Strong Buy
- DNTH Strong Buy
- Analyst Count
- SHEN 1
- DNTH 8
- Target Price
- SHEN $26.00
- DNTH $54.00
- AVG Volume (30 Days)
- SHEN 338.3K
- DNTH 369.1K
- Earning Date
- SHEN 07-31-2025
- DNTH 08-07-2025
- Dividend Yield
- SHEN 0.75%
- DNTH N/A
- EPS Growth
- SHEN N/A
- DNTH N/A
- EPS
- SHEN N/A
- DNTH N/A
- Revenue
- SHEN $349,477,000.00
- DNTH $4,854,000.00
- Revenue This Year
- SHEN $11.97
- DNTH N/A
- Revenue Next Year
- SHEN $9.07
- DNTH N/A
- P/E Ratio
- SHEN N/A
- DNTH N/A
- Revenue Growth
- SHEN 20.36
- DNTH 17.87
- 52 Week Low
- SHEN $9.77
- DNTH $13.37
- 52 Week High
- SHEN $16.89
- DNTH $32.27
- Technical
- Relative Strength Index (RSI)
- SHEN 49.84
- DNTH 69.33
- Support Level
- SHEN $13.13
- DNTH $23.24
- Resistance Level
- SHEN $13.76
- DNTH $25.41
- Average True Range (ATR)
- SHEN 0.41
- DNTH 1.44
- MACD
- SHEN 0.13
- DNTH 0.34
- Stochastic Oscillator
- SHEN 67.76
- DNTH 96.41
About SHEN Shenandoah Telecommunications Co
Shenandoah Telecommunications Company, with its subsidiaries, provides various broadband communication products and services via its wireless, cable, fiber optic, and fixed wireless networks to customers in the Mid-Atlantic United States. The company operates through one business unit: Broadband. The broadband segment provides broadband Internet, video, and voice services to residential and commercial customers. The broadband segment generates the vast majority of the company's revenue, with the bulk of sales flowing from residential and small, and medium businesses within the broadband unit.
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.